2004-2005 Grant Cycle : Research Grants Awarded
Biology of Breast Cancer
Role of Cyclin E in the Presence or Absence of CDK2 in Breast Tumorigenesis
said akli, PhD
University of Texas M.D. Anderson Cancer Center
$249,999
Cell Cycle Checkpoint Functions of the BRCA1/BARD1 Tumor Suppressor Complex
Richard Baer, PhD
Columbia University
$250,000
Regulation of the Preferential Skeletal Metastasis of Breast Cancers by Runx2
George Barnes, PhD
Boston University
$249,661
A TGF-beta Responsive Gene Therapy Vector (TRGT) that Specifically Kills Metastatic Breast Cancer
Stacy Blain, PhD
SUNY Downstate Medical Center
$245,857
The Role of Androgen Receptor Signaling in the Breast: Potential Disruption by Synthetic Progestins Used in Hormone Replacement Therapy
Lisa Butler, PhD
University of Adelaide
$249,999
Understanding the Tumor Suppression Function of BRCA1
Junjie Chen, PhD
Yale University
$250,000
The Role of KLF5 Transcription Factor Degradation in Breast Cancer
Ceshi Chen, PhD
Albany Medical College
$249,995
The Role of Chemokines and Their Receptors in Breast Cancer
Gina Chung, MD
Yale University
$250,000
Cooperation of Adipocytes with Breast Cancer Cells Promotes an Invasive Phenotype
Frank Church, PhD
University of North Carolina at Chapel Hill
$250,000
Prolyl Isomerase Function in Breast Cancer
Charles Clevenger, MD, PhD
Northwestern University
$249,999
Investigating the Role of the NFAT Signaling Pathway in Mammary Tumorigenesis
Neil Clipstone, BSc, PhD
Loyola University in Chicago
$250,000
Characterizing the Beta-Catenin Transgenic Model of Hormone-Independent Breast Cancer
PAMELA COWIN, PhD
New York University School of Medicine
$250,000
DNA Repair and the Etiology of Estrogen Receptor Positive Breast Cancer
David Crowe, PhD
University of Southern California
$250,000
Transcription Profiling of Protein Kinase C Activation in a Panel of Breast Cancer Cells Identifies a Strong Genetic Signature Consistent with Invasion and Metastasis
Heather Cunliffe, PhD
Translational Genomics Research Institute
$250,000
Does Heat Shock Protein 27 (Hsp27) Play Any Immunomodulatory Role in Breast Cancer?
Asit De, PhD
University of Rochester Medical Center
$249,922
Endothelin-1 Effects on the Development of Breast Cancer Bone Metastases
Didier Dreau, PhD
University of North Carolina at Charlotte
$218,812
The Role of Six1, and its Target Cyclin A1, in Breast Cancer
Heide Ford, PhD
University of Colorado Health Sciences Center
$250,000
Regulation of Prolactin Receptor Stability and Signaling by Ras Oncogene
Serge Fuchs, MD, PhD
University of Pennsylvania
$250,000
Analysis of O-glycans Involved in Lung Metastasis of Breast Cancer
Michiko Fukuda, PhD
The Burnham Institute
$250,000
Conditional Loss of the Mitotic Spindle Checkpoint in Chromosomal Instability and Tumorigenesis
Andrei Goga, MD, PhD
University of California, San Francisco
$250,000
Role of Telomerase and Telomeres in the Tumorigenesis of Breast Cancer
Jianlin Gong, MD
Boston University
$250,000
Inhibition of Leptin Signaling for Treatment of Breast Cancer
Ruben-Rene Gonzalez, PhD
Boston Biomedical Research Institute
$250,000
Role of the Breast Cancer Cell 2 (BRCC2) Tumor Suppressor Gene in Early-Onset Breast Cancer
Bassem Haddad, MD
Georgetown University
$250,000
The FGF Receptor is a Target for N-Cadherin in Breast Cancer Invasion
Rachel Hazan, PhD
Albert Einstein College of Medicine of Yeshiva University
$250,000
Incidence of DSS1 Mutations in High Risk Breast Cancer Families
William Holloman, PhD
Weill Medical College of Cornell University
$250,000
Molecular Mechanisms Underlying Aggressive Conversion of Dormant Breast Cancer Metastasis
Yibin Kang, PhD
Princeton University
$250,000
Characterization of Survivin Contribution to ErbB2-Mediated Drug Resistance
Irene Kazhdan, MD, PhD
University of Texas Health Science Center at San Antonio
$249,856
Characterization of a Novel Protein Implicated in Breast Cancer Progression
Kum KUm Khanna, PhD
The Queensland Institute of Medical Research
$248,250
Breast Cancer Stem Cells in the Formation of Bone Metastasis
Charlotte Kuperwasser, PhD
Tufts University School of Medicine
$250,000
The Roles Of Selenium Compounds In Inhibiting Proliferation And Metastasis Of Breast Cancer
Andrew Lane, PhD
University of Louisville
$250,000
Transcriptional Gene Interactions in Breast Cancer: Discovery and Analysis of Risk-Associated Regulatory Polymorphisms Combining Microarray and Linkage Analyses
Garry Larson, PhD
Beckman Research Institute of the City of Hope
$249,998
Genes Providing Resistance to Tamoxifen: Development and Validation of Clinical Biomarkers
Victor Levenson, MD, PhD
Northwestern University
$250,000
Identification of Estrogen Regulated Metastasis-Associated Genes Involved in Breast Cancer Bone Metastases
Anait Levenson, MD, PhD
Northwestern University
$250,000
Wip1 As A Novel Therapeutic Target For Human Breast Cancer
Yong Liao, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Molecular Imaging of CXCR4 in Breast Cancer: Effects on Tumor Angiogenesis
Gary Luker, MD
University of Michigan Medical School
$250,000
The Role of Osteoprotegrin-Ligand in Progesterone-Dependent Mammary Morphogenesis and Tumorigenesis
John Lydon, PhD
Baylor College of Medicine
$249,999
Toward Complete Inhibition of Spontaneous Mammary Tumors by a Combinational HSP110-HER-2/neu Chaperone Vaccine
Masoud Manjili, VMD, PhD
Virginia Commonwealth University
$249,380
EphA2, a Novel Target for Breast Cancer Therapy
Kathy Miller, MD
Indiana University
$250,000
Promiscuous Her3 signaling; A New Target in the Treatment of Breast Cancer
Mark Moasser, MD
University of California, San Francisco
$250,000
Designer Transcription Repressors: Toward the Treatment of Endocrine Resistant Breast Cancers
Mesut Muyan, DVM, PhD
University of Rochester
$249,889
Reversal of Tumor-Induced Immune Suppression
Suzanne Ostrand-Rosenberg, PhD
University of Maryland Baltimore County
$250,000
Ginkgo Biloba Extract in the Treatment of Human Breast Cancer
Vassilios Papadopoulos, PhD
Georgetown University Medical Center
$250,000
Significance of Shc-dependent Signaling Pathways in Breast Cancer Angiogenesis
Morag Park, PhD
McGill University
$249,999
Invasive Breast Cancer: HBP1 as a Clinical and Molecular Predictor
Kurtz Paulson, PhD
Tufts-New England Medical Center
$250,000
A Candidate Breast and Ovarian Tumor Suppressor Gene on Chromosome 17p13.3
Nancy Phillips, MD
Saint Louis University
$250,000
The Role of HSF-1 in the Enhancement of Osteoclastogenesis and Bone Metastasis by the Hsp90 Inhibitor, 17-AAG
John Price, BSc (Hons), PhD
Monash University
$250,000
Tumor-Stromal Interactions in Breast Cancer Bone Metastasis
Janet Price, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
MLK3 Meets Pak1 in Breast Cancer: A Prognostic Factor and a Therapeutics Target
Ajay Rana, PhD
Texas A & M University Health Science Center
$250,000
BRCA1 Regulation of Progesterone Receptor Function in Breast Cancer
Eliot Rosen, MD, PhD
Georgetown University
$250,000
Molecular Basis of Bone Metastasis in Breast Cancer
Gary Sahagian, PhD
Tufts University School of Medicine
$250,000
MRJ: A Molecular Switch for Cell Cycle and Cancer Metastasis
Rajeev Samant, PhD
University of South Alabama
$250,000
Analysis of Proteomic Patterns in Breast Cancer and Associated Tumor Stroma
Melinda Sanders, M.D.
Vanderbilt University School of Medicine
$249,999
Novel Imaging Techniques to Compare Estrogen Receptor Structure in Tumors and Normal Tissues of Intact Living Animals
Fred Schaufele, PhD
University of California, San Francisco
$250,000
Prevention of Breast Cancer by Sphingolipids: Importance of EGFR Regulation
Eva Schmelz, PhD
Wayne State University
$250,000
Cross-Talk Between ER Coregulators and Growth Factor Pathways in Breast Cancer Endocrine Resistance
Dipali Sharma, PhD
Emory University
$249,618
Roles of BIK Apoptosis-inducing Protein in Breast Cancer
Toshihiro Shioda, MD, PhD
Massachusetts General Hospital
$249,565
STAT5 as a Common Mediator of Estrogen and Growth Factor Signaling in Breast Cancer
Corinne Silva, PhD
University of Virginia
$249,814
The Cul3 Ubiquitin Ligase Is A Potential Marker for Breast Epithelial Tumorigenesis
Jeffrey Singer, BS, MS, PhD
Brown University
$250,000
Targeting Indoleamine 2,3-Dioxygenase to Block Breast Cancer Metastasis
Todd Skaar, PhD
Indiana University
$250,000
The Stroma as a Gatekeeper of Tumor Development
Ana Soto, MD
Tufts University
$250,000
Significance of Histone Deacetylase Inhibitors in Breast Cancer
Rakesh Srivastava, PhD
Univ. of Texas Health Center at Tyler
$250,000
Stat5 a Novel Therapeutic Protein for Breast Cancer Invasion and Mesenchymal Transition Regulation
Ahmed Sultan, MMS, PhD
Georgetown University
$250,000
Role of BRCA2 in Homology-Directed Repair of DNA Breaks
Patrick Sung, Dphil
Yale University
$250,000
Role of Coagulant Proteases in Breast Cancer Cell Invasion
JoAnn Trejo, PhD
University of North Carolina at Chapel Hill
$250,000
Value of molecular markers in predicting long-term outcome in ductal carcinoma in situ of the breast.
Christopher Umbricht, MD, PhD
Johns Hopkins University
$250,000
Phenotypic and Genomic Alterations in Epithelial Atypia and In Situ Breast Neoplasia
Frederic Waldman, MD, PhD
University of California, San Francisco
$249,967
Novel Targeting of TGFb in Osteolytic Metastasis
Mark Waltham, PhD
St. Vincent's Institute of Medical Research
$250,000
Cyclin D1 Regulation of Nuclear Receptor Function
Chenguang Wang, PhD
Georgetown University
$250,000
Directed Kinome Resequencing to Define New Targeted Therapies for “Basal-Like” Breast Cancer
Mark Watson, MD, PhD
Washington University
$249,554
Defining the Oncogenic Role of NPM/B23 Through Ribosome Biology
Jason Weber, PhD
Washington University
$249,209
Role of the BRCA1-FANCD2 Pathway in the Repair of DNA Double-Strand Breaks by Non-Homologous Recombination
Henning Willers, MD
Massachusetts General Hospital
$249,602
TWEAK: A New Molecular Target for Breast Cancer Therapy?
Jeffrey Winkles, PhD
University of Maryland School of Medicine
$249,929
Development of Glycosylation-based Therapies for Breast Cancer: Targeting Sialic Acid-Mediated Metastasis with Metabolic Analogs that Modulate Sialoside Biosynthesis
Kevin Yarema, BS & PhD
The Johns Hopkins University
$250,000
Cancer Control, Survivorship and Outcomes Research
Improving Informed Consent: A Randomised Controlled Trial of a Decision Aid for Women Invited to Participate in a Breast Cancer Prevention Trial (IBIS-2)
Phyllis Butow, PhD
University of Sydney
$244,000
Linking Lymphedema to Disorders of Lymphangiogenesis
Mary Kosir, MD
Wayne State University
$250,000
Breast Cancer Prevention: Methods of Risk Communication
Elissa Ozanne, PhD
Massachusetts General Hospital
$250,000
Yoga of Awareness Program for Menopausal Symptoms in Women at High Risk for Breast Cancer
Laura Porter, PhD
Duke University
$250,000
Feasibility of Physical Activity and Relaxation Training for Cancer Survivors
Carolyn Rabin, PhD
Miriam Hospital
$242,334
Early Detections, Diagnosis, and Prognosis
Identification and Differentiation of Breast Masses by a Novel Imaging Method
Azra Alizad, MD
Mayo Clinic College of Medicine
$250,000
Metabolic Imaging of Breast Cancer Glycosylation
Carolyn Bertozzi, BS, PhD
University of California, Berkeley
$249,999
Contrast-Enhanced Dual Energy Mammography
John Boone, PhD
University of California, Davis
$250,000
A New MRI Dextran-Based Contrast Agent for Early Detection and Diagnosis of Breast Cancer
Yuko Kono, MD, PhD
University of California, San Diego
$249,920
Spiegelmers as Inhibitors and Targeting Vehicles Against ErbB Receptors
Ralf Landgraf, PhD
University of California, Los Angeles
$249,936
Identification and Validation of Biomarkers for Breast Cancer in Nipple Aspiration Fluid
Jinong Li, PhD
Johns Hopkins University
$249,761
Imaging Breast Cancer Markers with Nanoparticle Enhanced Ultrasound
Jun Liu, PhD
The Ohio State University
$249,604
Tc-99m Labeled Multivalent RGD peptide for Breast Cancer Imaging
Shuang Liu, PhD
Purdue University
$243,973
Positron Emission Mammography Camera with Avalanche Gain
Alla Reznik, PhD
Sunnybrook and Women’s College Health Sciences Centre
$250,000
Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as a Potential Screening Tool for Women at Increased Risk of Breast Cancer
Deborah Rhodes, MD
Mayo Clinic Rochester
$249,900
Protein Signatures of Microinvasive (ER-) and Adjacent Noninvasive (ER+) Cell Clusters During the Progression of In Situ Lesions to Invasive Carcinomas
Qing-Xiang Sang, PhD
Florida State University
$249,946
F18-PET Detection of Breast Cancer Micrometastasis by CXCR4 Antagonist
Hyunsuk Shim, PhD
Emory University
$250,000
Protein Microarrays for the Detection of Breast Cancer
Michael Tainsky, PhD
Wayne State University
$250,000
Mechanism of Protein Kinase C Alpha-Mediated Tamoxifen-Resistant Breast Cancer
Debra Tonetti, PhD
University of Illinois
$249,912
A Novel Approach to Monitor Genetic Changes Associated with Breast Cancer Progression
Jonathan Uhr, MD
University of Texas Southwestern Medical Center at Dallas
$248,385
New PET Reporter Probes for Imaging HSV-tk Gene Expression in Breast Cancer
Qi-Huang Zheng, PhD
Indiana University
$250,000
Etiology
A Prospective Study of Alcohol Intake, Genetic Susceptibility and Breast Cancer Overall Health Risk
Rosa Crum, MD, MHS
Johns Hopkins University Bloomberg School of Public Health
$249,632
A Comprehensive Genomic Approach to Characterize the Role of Genetic Variation in IGF Receptor Genes in Relation to Breast Cancer Risk: The Multiethnic Cohort
Christopher Haiman, ScD
University of Southern California
$250,000
LRBA: A Target for More Effective Breast Cancer Treatments
William Kerr, PhD
H. Lee Moffitt Cancer Center and Research Institute
$249,999
Prevention
A Novel MUC1 Targeted Vaccine for the Treatment of Breast Cancer
Virginia Borges, MD
University of Colorado Health Science Center
$240,335
Sensitizing ER-Negative Breast Cancer Cells to Tamoxifen-Induced Apoptosis by a Novel PDK-1 Inhibitor
Ching-Shih Chen, PhD
Ohio State University
$250,000
A New Animal Model for Breast Cancer Development in Obese Post-Menopausal Women: Mechanism and Role of Diet
Reza Hakkak, PhD
Arkansas Children's Hospital Research Institute
$250,000
Activation of FOXO Tumor Suppressor for Breast Cancer Therapy and Prevention
Mickey Hu, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Artemisinin and Artemisinin-Tagged Transferrin for Prevention and Treatment of Breast Cancer
Henry Lai, PhD
University of Washington
$249,663
Mechanisms of Mult-Drug Resistance in Breast Cancer Chemotherapy
Judy Raucy, BS, MS, PhD
California Toxicology Research Institute
$250,000
INK4/ARF in Parity-Induced Protection of Breast Cancer
Thenaa Said, PhD
Baylor College of Medicine
$250,000
Scientific Model Systems
Imaging the Molecular Mechanisms of DNA Damage Repair
Eric Greene, PhD
Columbia University
$250,000
Role of Separase in Breast Cancer
Debananda Pati, PhD
Baylor College of Medicine
$250,000
Treatment
Devlopment of Breast Cancer Targeting Gene Therapy Vectors
Michael Barry, PhD
Baylor College of Medicine
$249,790
A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In-Situ of the Breast
Tara Breslin, MD
University of Wisconsin System
$84,242
Pre-Clinical Evaluation of Novel Hsp90 Inhibitors in Breast Cancer
Gabriela Chiosis, PhD
Memorial Sloan-Kettering Cancer Center
$250,000
Using HIF-1 Blockade to Improve Chemotherapy Efficacy in Human Breast Cancer
Mark Dewhirst, DVM, PhD
Duke University
$249,998
A Novel Vascular Targeting Antibody, 3G4, Enhances the Therapeutic Efficacy of Docetaxel Against Drug Resistant Breast Cancer and Metastases
Xianming Huang, PhD
UT Southwestern Medical Center at Dallas
$247,318
Targeting the Cell Cycle in Breast Cancer Treatment
Kelly Hunt, MD
University of Texas M.D. Anderson Cancer Center
$249,819
Characterization of Breast Motion and its Dosimetric Consequences
Robert Jeraj, PhD
University of Wisconsin, Madison
$250,000
P450-armed Replication-Specific/Adaptive Adenovirus for Chemo-resistant Breast Cancer Treatment
Youssef Jounaidi, PhD
Boston University
$249,867
Targeting PPARgamma by CDDO: A Novel Therapy for Resistant Breast Cancer
Marina Konopleva, MD, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Her2-Targeted Adenovirus Vectors for Imaging and Gene Therapy of Breast Cancer
Victor Krasnykh, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
A Lymph Node Targeted Anti-Cancer Drug Delivery System for Breast Cancer Metastases Based on Calcium Phosphate Particulates
Liisa Kuhn, PhD
University of Connecticut Health Center
$250,000
RNA Interference as a Novel Approach to Target Cyclin E Overexpression in Breast Cancer
Kaiyi Li, PhD
Baylor College of Medicine
$250,000
Mesenchymal Stem Cells as Cellular Delivery Vehicles for Control of Metastatic Breast Cancer
Frank Marini, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Auger Electron Emitters for Breast Cancer Radioimmunotherapy
M. Jules Mattes, PhD
Center for Molecular Medicine and Immunology
$250,000
The Plasminogen Activator System as a Target for Breast Cancer Virotherapy
Jaime Merchan, MD, MMSc
University of Miami
$250,000
Development of Selective AP-Site Directed Drugs in Breast Cancer
Nouri Neamati, PhD
University of Southern California
$250,000
Assessment of Adipose Tissue Engineering to Restore the Postmastectomy Breast
Charles Patrick Jr, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Epoxygenase Mechanisms of Breast Cancer Progression
David Potter, MD, PhD
Indiana University
$250,000
VSV-G Pseudotyped, Semi-Replication-Competent Vector for Breast Cancer Gene Therapy
Jian Qiao, PhD and MD
Mayo Clinic
$250,000
Interactions of Black Cohosh Extracts with Doxorubicin: Possible Mechanisms
Sara Rockwell, PhD
Yale University
$250,000
Targeted Immunotherapeutic Strategies in Breast Cancer
Andrew Scott, MB BS, FRACP
Ludwig Institute for Cancer Research
$249,998
Cyclooxygense-2 Protein and Tamoxifen Resistance in Breast Cancer
Ana Tari, PhD
University of Texas M.D. Anderson Cancer Center
$249,805
Intensity Modulated Radiotherapy for Treatment of Breast Cancer Patients in Prone Position
Julia White, MD
Medical College of Wisconsin
$249,954
Optimizing Oral Chemotherapy in Breast Cancer Using Fixed Dose Schedules: The Identification of Predictive Markers of Response and Toxicity to Capecitabine
Antonio Wolff, MD
The Sidney Kimmel Cancer Center at Johns Hopkins
$250,000
Intensity Modulated Breast Irradiation Under the Guidance of PET/CT Imaging
Lei Xing, PhD
Stanford University
$250,000
Enhancement of Radiotherapy of Breast Cancer by a Novel Chemoradiosensitizing Agent
Li-Xi Yang, MD, PhD
Calfornia Pacific Medical Center Research Institute
$249,998
* Pending executed agreement
